Out-licensing

Antigens for the Diagnosis and Immunotherapy of Allergic Disorders

Introduction/Background

Antigens are used for diagnosis as well as therapy of allergic disorders. These antigens have been selected on the basis of extensive research carried on the cases at leading clinics and research centres. Subsequently the results of these experiments and trials were successfully launched for commercial production. The demand for antigens has been growing over fast few years as evident from rapid proliferation of allergy treatment clinic in various parts of the country. There are about 120 such antigens have been developed for which the know-how is ready for transfer. Manufacture, marketing and application of these antigens are done as per the guidelines as stipulated by Drugs Controller of India.

Aims/Hypothesis

There is a need for the development of novel antigens for therapeutic and diagnostic purposes.

Results

We have prepared antigens from various kinds of substances which are themselves the causative agent for a particular allergy. These are pollens, insects, fungi, danders, feathers, food etc. After [re[aratopm they are preserved at a very low temp (4oC) and tested (skin) before substances based on which antigens are available.

Hyposensitization should be instituted only with substances incriminated as causative agents after a careful consideration of history and other diagnostic tests. Simultaneously inclusion of too many allergens in the injection programme should be avoided. The best results are obtained with injections of single allergen at a time. In any case, it is not advisable to mix together more than three unrelated allergens selected for hypo sensitization should be preserved in proportion to their importance as judged from the clinical history of attacks coinciding with prevalence of allergens in the patients environments. The total volume of the prescribed allergens should not exceed five millilitres which is the maximum volume dispensed in a single trial. In cases of seasonal allergy, dose of allergen included in the therapy, may be reduced during the peak season, if necessary.

Conclusion

Novel antigens have been developed for the diagnosis and immunotherapy of allergic disorders.

Relevance/Opportunity

Please contact if you are interested in forming licensing or codevelopment partnerships.

Preclinical